Open Access
Open Peer Review

This article has Open Peer Review reports available.

How does Open Peer Review work?

Hypercalcemia in a male-to-female transgender patient after body contouring injections: a case report

  • Koppany Visnyei1Email author,
  • Maria Samuel1,
  • Laura Heacock1 and
  • Jose A Cortes1
Journal of Medical Case Reports20148:71

https://doi.org/10.1186/1752-1947-8-71

Received: 24 April 2013

Accepted: 29 August 2013

Published: 26 February 2014

Abstract

Introduction

Body contouring injections by non-licensed providers are frequently sought out by a subset of the male-to-female transgender community. Although short-term side effects such as pulmonary embolism and injection site infection are well known, long-term consequences of such practices are less well studied.

Case presentation

Here we describe the case of a 40-year-old African American male-to-female transgender patient who presented to our institution with hypercalcemia and acute renal failure secondary to body contouring injections with industrial strength silicone by non-licensed providers, a decade prior to her visit. Work-up revealed an extensive granulomatous inflammatory process in the injection area resulting in electrolyte abnormalities and kidney injury. The patient’s lab results and symptoms responded well to long-term corticosteroid treatment and correlated with treatment adherence.

Conclusion

Affected patients can sometimes present with unusual clinical symptoms many years after silicone injections. In a constantly growing transgender community that often utilizes non-licensed providers for silicone injections, the medical community will likely face an increasing number of patients with long-term side effects of such practices. Therefore, it is imperative for physicians to recognize such cases promptly and initiate potentially life-saving treatment.

Keywords

LipogranulomaPTH-independentFiller

Introduction

Injections with various fillers, including mineral and organic oils like paraffin, petrolatum, camphor oil, silicone and vegetable oils have been practiced for more than a century. The first known injection in modern medical history was performed by an Austrian surgeon, Robert Gersuny in 1899 [1, 2]. He injected Vaseline®, a petroleum jelly brand, into the scrotal sack of a patient who underwent orchiectomy due to tuberculous epididymitis. His peer, Eckstein established the use of paraffin as an alternative to petroleum jelly, since it had a higher melting temperature (65°C) and therefore did not soften after the injection. Paraffin was injected in a semi-liquid state after heating, and solidified as it got colder, remaining stable and inert in the human body [1]. Soon other indications followed with both Vaseline® and paraffin, which were used to treat various medical conditions including fistulae, nasal defects and micrognathia, but were also used for wrinkles and body part augmentation, mostly in the breasts and the penis [1]. Such injections remained popular for the first few decades of the 20th century, until long-term side effects became evident in the form of paraffinomas and lipogranulomas. These tumors developed through the dissemination of the foreign material and were extremely difficult to treat [3, 4].

Today, an entire century later, we are witnessing a renaissance of body filler injections, albeit with much improved techniques and most importantly, refined, high-tech materials. While such materials seem to enable a relatively safe and side effect poor application, a large number of patients use cheap and unpurified industry-grade products, seemingly due to their financial and accessibility benefits. Additionally, these fillers are often administered by non-licensed providers, exposing patients to further risk of developing health problems. This is a growing problem in distinct subcultures, like the transgender community, where body-contouring is a much sought-after part of body image transformation.

While immediate and short-term complications of such practices are well known and can be diagnosed relatively easily, much less is known about long-term complications, which are also more challenging to recognize [3, 5, 6]. The major problem is still the development of foreign body granulomatous reactions, and various associated medical conditions. Here we present a case of a transgender patient who presented to our institution with unusual and remarkably serious long-term complications of hypercalcemia and kidney failure after industry-grade silicone injections for body contouring purposes.

Case presentation

A 40-year-old African American male-to-female transgender patient presented with malaise, dysuria, abdominal pain, increased thirst and blurred vision. The patient’s medical history included human immunodeficiency virus (HIV) infection and extensive body contouring injections with industry-grade silicone a decade prior. On physical exam, the patient exhibited massive, hardened, painful and somewhat erythematous bilateral subcutaneous deposits in the gluteal and thigh area (Figure 1). Laboratory studies revealed hypercalcemia (12.3mg/dl, norm: 8.8-10.3mg/dl) and acute kidney injury with elevated creatinine (1.56mg/dl, patient’s baseline 0.70mg/dl, norm: 0.6-1.2mg/dl). The patient had a viral load of <75 copies/ml and a CD4 count of 361 cells/mm3 while on Isentress® and Combivir® antiretroviral regimen. She had normal 1,25 dihydroxy-vitamin D (calcitriol) level (47pg/ml; norm: 15-75pg/ml), decreased 25-hydroxyvitamin D (calcidiol) level (16ng/ml; norm: 30-80 ng/ml) and decreased parathyroid hormone (PTH) <2.0pg/ml (norm: 10-60pg/ml).The patient underwent gallium-67 uptake scan that showed diffuse tracer uptake in the perigluteal soft tissue corresponding to the subcutaneous densities on physical exam. Computed tomography (CT) images showed large amounts of diffusely infiltrating granulomatous tissue (Figure 2). Groin lymph node biopsy showed benign reactive changes with histiocytes, lipid-containing vacuoles, inflammatory cells and occasional multinucleated giant cells, consistent with lipogranuloma (Figure 3). The patient’s remaining work-up including chest x-ray, chest CT, anti-nuclear antibody and TSH levels, QuantiFERON®-TB Gold In-Tube Test and fecal ova and parasite test revealed no abnormalities.
Figure 1

Physical exam findings in the area of silicone injections. The patient presented with massive, hardened and painful subcutaneous deposits in the bilateral gluteal and thigh area, one decade after extensive industry-grade silicone injections.

Figure 2

Imaging data showing extensive grannulomatous disease in the hip region. A - Axial computed tomography (CT) images showing large amounts of diffusely infiltrating granulomatous tissue (arrows). B - Gallium-67 uptake scan showing diffuse tracer uptake in the perigluteal soft tissue, corresponding to the subcutaneous densities on physical exam. Images were taken before (i) and after (ii) initiation of systemic corticosteroid therapy, improving the patient’s condition over time.

Figure 3

Groin lymph node biopsy showing benign reactive changes consistent with lipogranuloma. Note the histiocytes, lipid-containing vacuoles, inflammatory cells and occasional multinucleated giant cells (inset).

Based on the physical, laboratory, imaging and histological findings, the diagnosis of hypercalcemia caused by silicone-induced granulomatous disease was established. In this condition, PTH is typically suppressed by high calcium levels and hypercalcemia occurs due to PTH-independent extrarenal production of 1,25 dihydroxy-vitamin D from 25-hydroxyvitamin D by activated mononuclear cells [7].

In our patient, additional causes of hypercalcemia, like hyperparathyroidism, myeloma, bony metastases, paraneoplastic syndrome, milk-alkali syndrome, sarcoidosis, tuberculosis, strongyloidiasis or excessive use of vitamin D were ruled out, with laboratory tests and imaging studies as described above. Additionally, the patient did not admit to exogenous vitamin A or estrogen administration and was on continuous antiretroviral therapy without the possibility of immune reconstitution syndrome, which could have all resulted in, or contributed to hypercalcemia [8]. The patient responded well to intravenous hydration, pamidronate and methylprednisone treatment. Her pain subsided, the calcium level and kidney function normalized, and nuclear imaging showed a decreased level of inflammation (Figure 2B). Non-compliance with treatment resulted in increasing calcium levels (up to 18.0mg/dl), demonstrating the importance of the long-term use of corticosteroids. Of note, due to the excessive and diffusely infiltrating nature of her disease, the patient was deemed not to be a surgical candidate (Figure 4).
Figure 4

Corrected serum calcium levels over time. Note the gradually increasing calcium levels before treatment and the drop of calcium concentrations during therapy. Non-compliance with treatment resulted in repeatedly increasing calcium levels, demonstrating the importance of the long-term use of corticosteroids. Ga, gallium; Norm, normal.

Discussion

Injection of organic or inorganic oils has been described to lead to development of a foreign body reaction in the form of a chronic granulomatous inflammation. This happens after an acute inflammatory phase of several months followed by a latent phase that can last several years [9]. The average time to development of first clinical symptoms including sclerodermatous skin changes, tissue hardening, skin hyperpigmentation and development of subcutaneous lumps, nodules and occasional ulcerations, is approximately 6 years [10]. The tumors caused by granulomatous reaction are called oleomas, paraffinomas or siliconomas, depending on the foreign material involved.

Many foreign-body induced tumors have been described in the literature, however the major cause of presentation is almost always of cosmetic nature [4, 6]. Our case stands out due to the unusually serious presentation with clinically symptomatic hypercalcemia and renal failure. While the development of calcitriol-related hypercalcemia in granulomatous diseases in general has been well described, it has not been associated with body contouring-induced siliconomas. A potential possibility for the severe electrolyte changes in this particular case might be the unusually large amount of injected material and the large anatomic area involved.

Conversion of inactive vitamin D to its active form requires the enzyme 1-alpha-hydroxylase (also known as cytochrome p450 27B1 or CYP27B1), which is present in renal tubular cells, but can also be found at multiple extrarenal sites, including in immune cells involved in granulomatous diseases, like the alveolar macrophages of patients with sarcoidosis [11, 12]. The production of 1,25 dihydroxy-vitamin D is regulated by the inhibition of 1-alpha-hydroxylase activity in response to increased 1,25 dihydroxy-vitamin D levels, and by the intracellular inactivating enzyme 24-hydroxylase. Interestingly, while these inhibiting mechanisms are well established in renal tubular cells, they are much more limited in dendritic cells and macrophages (Figure 5). These latter ones exhibit very little inhibition of 1-alpha-hydroxylase activity, and also have a low concentration of 24-hydroxylase, suggesting a lack of a negative feed-back loop mechanism, resulting in the production of large amounts of 1,25 dihydroxy-vitamin D [13]. It has also been shown that in inflammatory cells, 1,25 dihydroxy-vitamin D production is enhanced by γ-interferon, which is produced by activated lymphocytes and alveolar macrophages in active sarcoidosis [14]. On the other hand, 1,25 dihydroxy-vitamin D has been shown to inhibit activated T helper cells and γ-interferon production. This suggests that the production of 1,25 dihydroxy-vitamin D by macrophages might represent a compensatory mechanism to inhibit the inflammatory process at the site of disease, by limiting T helper cell proliferation and lymphokine production [15]. Regardless of the modulatory effect of 1,25 dihydroxy-vitamin D on inflammatory processes, it is evident that granulomas provide a non-renal source of 1,25 dihydroxy-vitamin D. This has been shown in sarcoid lymph nodes as well as mononuclear cells isolated from tuberculosis patients [16, 17], but also in mineral-oil induced paraffinomas, where immunohistochemical studies showed increased 1-alpha-hydroxylase activity in macrophages within of the granulomatous tissue [6].
Figure 5

Production of active vitamin D in renal and immune cells. Vitamin D3 is initially 25-hydroxylated to the main circulating form of vitamin D, 25-hydroxy vitamin D. This molecule is then 1alpha-hydroxylated to the active form of vitamin D, 1,25-dihydroxy vitamin D. This binds to the vitamin D receptor (VDR) in the nucleus and forms heterodimers with the retinoid X receptor (RXR). The complex acts as a transregulatory complex, controlling transcription of several genes. The enzyme 24-hydroxylase acts as a negative feedback control pathway by synthesizing inactive 1, 24, 25-trihydroxy-vitamin D.

Elevated 1,25 dihydroxy-vitamin D levels lead to increased intestinal absorption and increased bone resorption of calcium, resulting in hypercalcemia, hypercalcuria, nephrocalcinosis and kidney stones, as well as decreased parathyroid hormone levels. Hypercalcemia is typically worsened by renal insufficiency. It usually varies with calcium intake and can be corrected with dietary restriction of calcium. Exposure to sunlight might also worsen hypercalcemia and can cause seasonal variation of calcium levels [15].

Of note, our patient had normal 1,25 dihydroxy-vitamin D levels upon presentation. One possible explanation for this is the low amount of 25 hydroxy-vitamin D that is available for hydroxylation by 1-alpha-hydroxylase. This would result in lower than expected 1,25 vitamin D levels, even in the presence of increased enzyme activity. Therefore, the relative ratio of 25 hydroxy and 1,25 dihydroxy vitamin D might be more informative than the absolute 1,25 dihydroxy vitamin D level in assessing enzymatic activity in this setting.

Depending on the anatomic location and the extension of the disease, surgical resection can be often performed, either with curative or non-curative, debulking intent. In the case of our patient, surgery was not an option, due to the bare extent of the disease and due to widespread tissue infiltration. Furthermore, the patient declined a figure-altering surgical procedure.

An important observation was that the synthesis of 1,25 dihydroxy-vitamin D in isolated alveolar macrophages of sarcoma patients markedly diminished by the addition of dexamethasone, in a dose-dependent manner [14]. This explains the response of hypercalcemia to steroid treatment in patients with sarcoidosis and other granulomatous diseases. Analogously, foreign material-induced granulomas can be treated conservatively with regionalized corticosteroid injections, especially in the case of smaller lesions. Minocycline, cyclosporine and allopurinol have been used with some success as well [18]. Of note, hydroxychloroquine and ketoconazole have been shown to be effective in treating hypercalcemia in sarcoidosis [19, 20]. In contrast to long-term steroids, their milder side effect profiles might make them preferable candidates, however their exact role in treating siliconomas and paraffinomas is still to be explored. In our patient’s case, due to extensive disease, systemic corticosteroid treatment was necessary along with specific calcium lowering management. For the latter, treatment options include reducing calcium intake, elimination of dietary vitamin D supplements, avoidance of sun exposure and if needed, bisphosphonates.

In our case, longitudinally measured calcium levels seemed to have correlated well with corticosteroid treatment and disease activity, as seen on imaging studies. Therefore, it might be a useful tool to monitor disease improvement or progression in patients presenting with extensive disease and severe hypercalcemia.

Renal failure has been extensively described in granulomatous diseases, like sarcoidosis. The main pathophysiological mechanism of kidney involvement seems to be a granulomatous inflammation confined to the tubulointerstitial compartment [21], however interstitial and membranous nephritis without any evidence of granuloma has been described as well [22]. The exact mechanism of development of renal failure in siliconoma or paraffinomas-associated granulomatous disease is still unclear however.

Conclusion

With a worldwide trend of increasing demand to undergo physique-altering procedures, in the transgender but also other communities, we can expect to see more patients with short and long-term complications of body contouring practices. Long-term complications include localized skin changes and the development of lipogranuloma. However, in case of more extensive disease, hypercalcemia can develop with potentially life-threatening complications. It will be important to recognize these symptoms as possible complications of foreign body injections, and to initiate treatment in a timely manner. Most importantly however, this report would like to stress the importance of informing patients about potential side effects of improper and large-scale body contouring practices by non-licensed providers.

Consent

Written informed consent was obtained from the patient for publication of this case report and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.

Declarations

Acknowledgements

The authors would like to thank Dr Adreienne M. Fleckman in the Department of Endocrinology for reviewing the manuscript, and Dr. Lawrence Kiss in the Department of Pathology at Beth Israel Medical Center for the histologic images.

Authors’ Affiliations

(1)
Department of Internal Medicine, Beth Israel Medical Center, Albert Einstein College of Medicine

References

  1. Glicenstein J: [The first "fillers", Vaseline® and paraffin. From miracle to disaster]. Annales de chirurgie plastique et esthetique. 2007, 52: 157-161. 10.1016/j.anplas.2006.05.003.View ArticlePubMedGoogle Scholar
  2. The classic reprint. Concerning a subcutaneous prosthesis: Robert Gersuny. (Uber eine subcutane Prothese. Zeitschrift f. Heilkunde Wien u Leipzig 21:199, 1900.). Translated from the German by Miss Rita Euerle. Plast Reconstr Surg. 1980, 65: 525-527. 10.1097/00006534-198004000-00025.Google Scholar
  3. Rollins CE, Reiber G, Guinee DG, Lie JT: Disseminated lipogranulomas and sudden death from self-administered mineral oil injection. Am J Forensic Med Pathol. 1997, 18: 100-103. 10.1097/00000433-199703000-00019.View ArticlePubMedGoogle Scholar
  4. Sclafani AP, Fagien S: Treatment of injectable soft tissue filler complications. Dermatol Surg. 2009, 35 (Suppl 2): 1672-1680.View ArticlePubMedGoogle Scholar
  5. Loke SC, Leow MK: Calcinosis cutis with siliconomas complicated by hypercalcemia. Endocr Pract. 2005, 11: 341-345. 10.4158/EP.11.5.341.View ArticlePubMedGoogle Scholar
  6. Moraitis AG, Hewison M, Collins M, Anaya C, Holick MF: Hypercalcemia associated with mineral oil-induced sclerosing paraffinomas. Endocr Pract. 2013, 19: e50-e56. 10.4158/EP12092.CR.View ArticlePubMedGoogle Scholar
  7. Adams JS, Singer FR, Gacad MA, Sharma OP, Hayes MJ, Vouros P, Holick MF: Isolation and structural identification of 1,25-dihydroxyvitamin D3 produced by cultured alveolar macrophages in sarcoidosis. J Clin Endocr Metab. 1985, 60: 960-966. 10.1210/jcem-60-5-960.View ArticlePubMedGoogle Scholar
  8. Tsao YT, Wu YC, Yang CS, Lin YT: Immune reconstitution associated hypercalcemia. Am J Emerg Med. 2009, 27: 629-e621-623View ArticlePubMedGoogle Scholar
  9. Legaspi-Vicerra ME, Field LM: Paraffin Granulomata, "Witch's Chin," and Nasal Deformities: excision and reconstruction with reduction chinplasty and open rhinotomy resection. J Clin Aesthet Dermatol. 2010, 3: 54-58.PubMedPubMed CentralGoogle Scholar
  10. Cabral AR, Alcocer-Varela J, Orozco-Topete R, Reyes E, Fernandez-Dominguez L, Alarcon-Segovia D: Clinical, histopathological, immunological and fibroblast studies in 30 patients with subcutaneous injections of modelants including silicone and mineral oils. Revista de investigacion clinica; organo del Hospital de Enfermedades de la Nutricion. 1994, 46: 257-266.PubMedGoogle Scholar
  11. Adams JS, Sharma OP, Gacad MA, Singer FR: Metabolism of 25-hydroxyvitamin D3 by cultured pulmonary alveolar macrophages in sarcoidosis. J Clin Invest. 1983, 72: 1856-1860. 10.1172/JCI111147.View ArticlePubMedPubMed CentralGoogle Scholar
  12. Zehnder D, Bland R, Williams MC, McNinch RW, Howie AJ, Stewart PM, Hewison M: Extrarenal expression of 25-hydroxyvitamin d(3)-1 alpha-hydroxylase. J Clin Endocr Metab. 2001, 86: 888-894.PubMedGoogle Scholar
  13. Hewison M, Zehnder D, Chakraverty R, Adams JS: Vitamin D and barrier function: a novel role for extra-renal 1 alpha-hydroxylase. Mol Cell Endocrinol. 2004, 215: 31-38. 10.1016/j.mce.2003.11.017.View ArticlePubMedGoogle Scholar
  14. Adams JS, Gacad MA: Characterization of 1 alpha-hydroxylation of vitamin D3 sterols by cultured alveolar macrophages from patients with sarcoidosis. J Exptl Med. 1985, 161: 755-765. 10.1084/jem.161.4.755.View ArticleGoogle Scholar
  15. Rizzato G: Clinical impact of bone and calcium metabolism changes in sarcoidosis. Thorax. 1998, 53: 425-429. 10.1136/thx.53.5.425.View ArticlePubMedPubMed CentralGoogle Scholar
  16. Mason RS, Frankel T, Chan YL, Lissner D, Posen S: Vitamin D conversion by sarcoid lymph node homogenate. Ann Intern Med. 1984, 100: 59-61. 10.7326/0003-4819-100-1-59.View ArticlePubMedGoogle Scholar
  17. Cadranel J, Garabedian M, Milleron B, Guillozo H, Akoun G, Hance AJ: 1,25(OH)2D2 production by T lymphocytes and alveolar macrophages recovered by lavage from normocalcemic patients with tuberculosis. J Clin Investigation. 1990, 85: 1588-1593. 10.1172/JCI114609.View ArticleGoogle Scholar
  18. Arin MJ, Bate J, Krieg T, Hunzelmann N: Silicone granuloma of the face treated with minocycline. J Am Acad Dermatol. 2005, 52: 53-56.View ArticlePubMedGoogle Scholar
  19. Barre PE, Gascon-Barre M, Meakins JL, Goltzman D: Hydroxychloroquine treatment of hypercalcemia in a patient with sarcoidosis undergoing hemodialysis. Am J Med. 1987, 82: 1259-1262. 10.1016/0002-9343(87)90237-3.View ArticlePubMedGoogle Scholar
  20. Adams JS, Sharma OP, Diz MM, Endres DB: Ketoconazole decreases the serum 1,25-dihydroxyvitamin D and calcium concentration in sarcoidosis-associated hypercalcemia. J Clin Endocr Metab. 1990, 70: 1090-1095. 10.1210/jcem-70-4-1090.View ArticlePubMedGoogle Scholar
  21. Agrawal V, Crisi GM, D'Agati VD, Freda BJ: Renal sarcoidosis presenting as acute kidney injury with granulomatous interstitial nephritis and vasculitis. Am J kidney Dis. 2012, 59: 303-308. 10.1053/j.ajkd.2011.09.025.View ArticlePubMedGoogle Scholar
  22. Ponce C, Gujral JS: Renal failure and hypercalcemia as initial manifestations of extrapulmonary sarcoidosis. Southern Med J. 2004, 97: 590-592. 10.1097/00007611-200406000-00016.View ArticlePubMedGoogle Scholar

Copyright

© Visnyei et al.; licensee BioMed Central Ltd. 2014

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited.